Metabolic disease and adverse events from immune checkpoint inhibitors

CONCLUSIONS: Overweight patients with fewer metabolic comorbidities were at increased risk for irAEs. This study provides an important insight that BMI should be evaluated in the context of associated metabolic comorbidities in assessing risk of irAE development and ICI immune response.PMID:34552304 | PMC:PMC8451971 | DOI:10.1530/eje-20-1362
Source: European Journal of Endocrinology - Category: Endocrinology Authors: Source Type: research